HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo

Hoon Han Ki, Jewon Ryu, Hee Hong Kyung, Je Sang Ko, Kim Pak Youngmi, Jae Bum Kim, Wook Park Seong, Joong Kim Jae

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background - The migration of circulating monocytes to the arterial wall during atherogenesis is largely modulated by activation of the CC chemokine receptor 2 (CCR2), a dominant monocyte chemotaxis receptor. The present study investigated whether 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition affects CCR2 gene expression and CCR2-dependent monocyte recruitment. Methods and Results - Competitive reverse transcription-polymerase chain reaction analysis and flow cytometry showed that simvastatin, an HMG-CoA reductase inhibitor, dose-dependently reduced monocyte CCR2 mRNA and protein expression. Treatment of 21 normocholesterolemic men with simvastatin (20 mg/d for 2 weeks) decreased CCR2 protein and mRNA expression in circulating monocytes. Promoter and electrophoretic mobility shift assays showed that simvastatin activated a peroxisome proliferator response element in THP-1 monocytes. Moreover, simvastatin-induced CCR2 downregulation was completely reversed by the synthetic peroxisome proliferator-activated receptor-γ antagonist GW9662. Simvastatin-treated monocytes showed little chemotaxis movement in response to monocyte chemoattractant protein-1 (MCP-1), a specific CCR2 ligand. Treatment of C57/BL6 mice with simvastatin (0.2 μg/g body weight IP, daily for 1 week) inhibited transmigration of CD80+ monocytes to the MCP-1-injected intraperitoneal space. Moreover, few circulating inflammatory cells from simvastatin-treated Sprague-Dawley rats (0.2 μg/g body weight IP, daily for 2 weeks) were recruited to the aortic wall of hypercholesterolemic littermates. Conclusions - The inhibition of CCR2/MCP-1-dependent monocyte recruitment by simvastatin may prevent excessive accumulation of monocytes in the arterial wall during atherogenesis.

Original languageEnglish
Pages (from-to)1439-1447
Number of pages9
JournalCirculation
Volume111
Issue number11
DOIs
Publication statusPublished - 2005 Mar 22
Externally publishedYes

Fingerprint

CCR2 Receptors
Chemokine CCL2
Coenzyme A
Simvastatin
Monocytes
Oxidoreductases
Chemotaxis
Atherosclerosis
Body Weight
Inhibition (Psychology)
Peroxisome Proliferators
Messenger RNA
Peroxisome Proliferator-Activated Receptors
Response Elements
Electrophoretic Mobility Shift Assay
Reverse Transcription
Sprague Dawley Rats
Flow Cytometry
Proteins
Down-Regulation

Keywords

  • Atherosclerosis
  • Cells
  • Receptors
  • Statins

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. / Ki, Hoon Han; Ryu, Jewon; Kyung, Hee Hong; Ko, Je Sang; Youngmi, Kim Pak; Kim, Jae Bum; Seong, Wook Park; Jae, Joong Kim.

In: Circulation, Vol. 111, No. 11, 22.03.2005, p. 1439-1447.

Research output: Contribution to journalArticle

Ki, Hoon Han ; Ryu, Jewon ; Kyung, Hee Hong ; Ko, Je Sang ; Youngmi, Kim Pak ; Kim, Jae Bum ; Seong, Wook Park ; Jae, Joong Kim. / HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. In: Circulation. 2005 ; Vol. 111, No. 11. pp. 1439-1447.
@article{82382cd92a0347ea8859cacdc4f1cfd7,
title = "HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo",
abstract = "Background - The migration of circulating monocytes to the arterial wall during atherogenesis is largely modulated by activation of the CC chemokine receptor 2 (CCR2), a dominant monocyte chemotaxis receptor. The present study investigated whether 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition affects CCR2 gene expression and CCR2-dependent monocyte recruitment. Methods and Results - Competitive reverse transcription-polymerase chain reaction analysis and flow cytometry showed that simvastatin, an HMG-CoA reductase inhibitor, dose-dependently reduced monocyte CCR2 mRNA and protein expression. Treatment of 21 normocholesterolemic men with simvastatin (20 mg/d for 2 weeks) decreased CCR2 protein and mRNA expression in circulating monocytes. Promoter and electrophoretic mobility shift assays showed that simvastatin activated a peroxisome proliferator response element in THP-1 monocytes. Moreover, simvastatin-induced CCR2 downregulation was completely reversed by the synthetic peroxisome proliferator-activated receptor-γ antagonist GW9662. Simvastatin-treated monocytes showed little chemotaxis movement in response to monocyte chemoattractant protein-1 (MCP-1), a specific CCR2 ligand. Treatment of C57/BL6 mice with simvastatin (0.2 μg/g body weight IP, daily for 1 week) inhibited transmigration of CD80+ monocytes to the MCP-1-injected intraperitoneal space. Moreover, few circulating inflammatory cells from simvastatin-treated Sprague-Dawley rats (0.2 μg/g body weight IP, daily for 2 weeks) were recruited to the aortic wall of hypercholesterolemic littermates. Conclusions - The inhibition of CCR2/MCP-1-dependent monocyte recruitment by simvastatin may prevent excessive accumulation of monocytes in the arterial wall during atherogenesis.",
keywords = "Atherosclerosis, Cells, Receptors, Statins",
author = "Ki, {Hoon Han} and Jewon Ryu and Kyung, {Hee Hong} and Ko, {Je Sang} and Youngmi, {Kim Pak} and Kim, {Jae Bum} and Seong, {Wook Park} and Jae, {Joong Kim}",
year = "2005",
month = "3",
day = "22",
doi = "10.1161/01.CIR.0000158484.18024.1F",
language = "English",
volume = "111",
pages = "1439--1447",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo

AU - Ki, Hoon Han

AU - Ryu, Jewon

AU - Kyung, Hee Hong

AU - Ko, Je Sang

AU - Youngmi, Kim Pak

AU - Kim, Jae Bum

AU - Seong, Wook Park

AU - Jae, Joong Kim

PY - 2005/3/22

Y1 - 2005/3/22

N2 - Background - The migration of circulating monocytes to the arterial wall during atherogenesis is largely modulated by activation of the CC chemokine receptor 2 (CCR2), a dominant monocyte chemotaxis receptor. The present study investigated whether 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition affects CCR2 gene expression and CCR2-dependent monocyte recruitment. Methods and Results - Competitive reverse transcription-polymerase chain reaction analysis and flow cytometry showed that simvastatin, an HMG-CoA reductase inhibitor, dose-dependently reduced monocyte CCR2 mRNA and protein expression. Treatment of 21 normocholesterolemic men with simvastatin (20 mg/d for 2 weeks) decreased CCR2 protein and mRNA expression in circulating monocytes. Promoter and electrophoretic mobility shift assays showed that simvastatin activated a peroxisome proliferator response element in THP-1 monocytes. Moreover, simvastatin-induced CCR2 downregulation was completely reversed by the synthetic peroxisome proliferator-activated receptor-γ antagonist GW9662. Simvastatin-treated monocytes showed little chemotaxis movement in response to monocyte chemoattractant protein-1 (MCP-1), a specific CCR2 ligand. Treatment of C57/BL6 mice with simvastatin (0.2 μg/g body weight IP, daily for 1 week) inhibited transmigration of CD80+ monocytes to the MCP-1-injected intraperitoneal space. Moreover, few circulating inflammatory cells from simvastatin-treated Sprague-Dawley rats (0.2 μg/g body weight IP, daily for 2 weeks) were recruited to the aortic wall of hypercholesterolemic littermates. Conclusions - The inhibition of CCR2/MCP-1-dependent monocyte recruitment by simvastatin may prevent excessive accumulation of monocytes in the arterial wall during atherogenesis.

AB - Background - The migration of circulating monocytes to the arterial wall during atherogenesis is largely modulated by activation of the CC chemokine receptor 2 (CCR2), a dominant monocyte chemotaxis receptor. The present study investigated whether 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibition affects CCR2 gene expression and CCR2-dependent monocyte recruitment. Methods and Results - Competitive reverse transcription-polymerase chain reaction analysis and flow cytometry showed that simvastatin, an HMG-CoA reductase inhibitor, dose-dependently reduced monocyte CCR2 mRNA and protein expression. Treatment of 21 normocholesterolemic men with simvastatin (20 mg/d for 2 weeks) decreased CCR2 protein and mRNA expression in circulating monocytes. Promoter and electrophoretic mobility shift assays showed that simvastatin activated a peroxisome proliferator response element in THP-1 monocytes. Moreover, simvastatin-induced CCR2 downregulation was completely reversed by the synthetic peroxisome proliferator-activated receptor-γ antagonist GW9662. Simvastatin-treated monocytes showed little chemotaxis movement in response to monocyte chemoattractant protein-1 (MCP-1), a specific CCR2 ligand. Treatment of C57/BL6 mice with simvastatin (0.2 μg/g body weight IP, daily for 1 week) inhibited transmigration of CD80+ monocytes to the MCP-1-injected intraperitoneal space. Moreover, few circulating inflammatory cells from simvastatin-treated Sprague-Dawley rats (0.2 μg/g body weight IP, daily for 2 weeks) were recruited to the aortic wall of hypercholesterolemic littermates. Conclusions - The inhibition of CCR2/MCP-1-dependent monocyte recruitment by simvastatin may prevent excessive accumulation of monocytes in the arterial wall during atherogenesis.

KW - Atherosclerosis

KW - Cells

KW - Receptors

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=15444368304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15444368304&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000158484.18024.1F

DO - 10.1161/01.CIR.0000158484.18024.1F

M3 - Article

VL - 111

SP - 1439

EP - 1447

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 11

ER -